Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This brand-new publication offers a guide through the complex landscape of regulations, standards, and interpretations surrounding software as a medical device.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 19 November 2013 | By Alexander Gaffney, RAC,
More than a year after initiating an investigation into "serious" pharmacovigilance shortcomings at Roche, EU regulators say they have found new evidence of unreported adverse events associated with the company's products, but that none will be withdrawn from the market.
In October 2013, UK regulators conducting an inspection of Roche said they found "Serious shortcomings" with respect to the company's pharmacovigilance practices and processes that resulted in nearly 80,000 adverse events going unreported to regulators.
Those findings were the result of a May 2012 inspection by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), which was conducting a routine inspection of the company's UK facility. Among the tens of thousands of adverse event reports were more than 15,000 reports of patient deaths, 23,000 suspected adverse reactions and 600 clinical trial-related adverse events. Those numbers have, according to Roche, been revised substantially downward since the initial reports.
Regulators cautioned that the reports did not imply causation, and were not necessarily even associated with the drug product being taken by consumers. Regulators were nevertheless furious, and immediately launched an investigation into whether any laws were broken and just as importantly if any medicines had previously unknown risks that might require them to be removed from the market.
The European Medicines Agency (EMA) has now released the results of its investigation, saying it has conducted a "thorough review" of the 19 medicines affected by Roche's lack of reporting.
Regulators said that while some new adverse events had been discovered that "had not previous been provided by Roche," those new effects did not substantially impact the benefit-risk assessment of any drugs to the point of requiring their withdrawal from the market.
The drugs included many of Roche's most popular products, such as Avastin, Herceptin, Pegasys, Tamiflu, Zelboraf, MabThera and Boniva.
Fortunately for Roche, EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that for all drugs, "There is no new advice regarding their use."
"However, as Roche continues to provide additional data as part of their obligatory follow-up, they are required to ensure that these data are included and considered in their routine pharmacovigilance activities, including the periodic cumulative reviews of the benefits and risks of these medicines," EMA wrote.
Roche, though, is still not in the clear. Under the terms of the infringement procedure launched against the company at the time of the launch of the investigation, it could be subject to massive fines.
Article 16.2 of EC No 658/2007 allows for the EC to impose a penalty of up to 5% of a company's revenue for the preceding year. Continued non-compliance can lead to an ongoing, periodic fine of 2.5% of the company's daily revenues until compliance is assured.
EMA said the conclusion of its investigation was "without prejudice to the infringement procedure."
EMA Statement
Tags: Roche, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.